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ABSTRACT
Objective: Heat shock protein 70 (HSP70) reduces the expression of cytochrome C, B-cell lymphoma-associated X, and cysteine-aspartic acid 
protease 3 (Caspase 3), in apoptosis of multiple organ dysfunction syndrome (MODS), and thereby can prevent death. Previous researchers used 
226 mg/kgBW/intraperitoneal (ip) of HSP70. This study aimed to determine the lowest effective dose of HSP70 to prevent death in sepsis mice 
model with MODS.
Methods: This was a randomized control trial conducted at Pusat Antar Universitas (PAU), Gadjah Mada University, Yogyakarta, Indonesia, from April 
1, 2017 to April 21, 2017. The study subjects were Balb/c strain mice. The drug used to induce death was lipopolysaccharides (LPS). The drug used to 
prevent death in this study was Rat HSP70. A sample of 25 mice was randomized into five groups with each consisting of five mice: (1) Control group 
with NaCl, (2) experimental group receiving LPS injection of 0.25 mg/kgBW/i.p, (3) experimental group receiving the same dose of LPS injection with 
HSP70 injection of 100 µg/kgBW/ip, (4) experimental group receiving the same dose of LPS injection with HSP70 injection of 200 µg/kgBW/ip, and 
(5) experimental group receiving the same dose of LPS injection with HSP70 injection of 300 µg/kgBW/ip. Percentage of live mice between groups 
was compared by Chi-square test.
Results: 3 days after intervention, 13 (86.7%) live mice in the experimental group with ≥100 µg/kgBW/i.p HSP70 were >2 (40%) live mice in the 
experimental group with <100 µg/kgBW/i.p HSP70, with p=0.038. All mice receiving ≥200 µg/kgBW/ip HSP70 in the experimental group were Alive 
3 days after intervention.
Conclusion: The lowest effective dose of HSP70 to prevent death in sepsis mice model with MODS is 200 µg/kgBW/ip. All mice are alive 3 days after 
receiving ≥200 µg/kgBW/ip HSP70.
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INTRODUCTION
Sepsis is a serious and complex health problem that can immediately lead 
to some worse situations, such as multiple organ dysfunction syndrome 
(MODS), septic shock, hospitalizations, and death [1-3]. The MODS can 
be defined as the development of potentially reversible physiologic 
derangement involving two or more organ systems not involved in the 
disorder that resulted in ICU admission and arising in the wake of a 
potentially life-threatening physiologic insult [4]. In MODS, apoptosis 
occurs as a vital component of various processes including normal cell 
turnover, proper development and functioning of the immune system, 
hormone-dependent atrophy, embryonic development and chemical-
induced cell death [5-7]. The term “apoptosis,” introduced by Kerr in 1972, 
refers to the morphological formation of apoptotic bodies in a cell [8].
There are two strategies that can be opted to address sepsis: 
(1) De-escalation and (2) heat shock protein (HSP). Antimicrobial de-
escalation has been defined as a mechanism whereby the provision 
of effective initial antibiotic treatment, particularly in cases of severe 
sepsis, is achieved while avoiding unnecessary antibiotic use that would 
promote the development of resistance. De-escalation or streamlining 
of empirical antimicrobial therapy on the basis of culture results and 
elimination of redundant combination therapy can more effectively 
target the causative pathogen, resulting in decreased antimicrobial 
exposure and substantial cost savings. Hence, de-escalation strategy 
can be used to treat patients with sepsis [9,10]. However, there are 
some challenges in implementing de-escalation. There is a natural 
propensity, particularly in severe sepsis, when the patient who has 
been very seriously ill is starting to get better, to stick with a treatment 
regimen that is working rather than change to an alternative agent [9].
HSPs are a group of such proteins that bind to such surfaces during 
assembly of large molecules and prevent the occurrence of incorrect 
union/interactions between parts/surfaces of the molecules [11]. 
In MODS, HSP 70 (HSP70) inhibits upstream and downstream 
mitochondria apoptosis by restricting cytochrome C (Cyt C), B-cell 
lymphoma (BCL)-associated X (BAX), and caspase 3 expressions, which 
eventually decreases mortality rate [12,13].
As previous studies have shown, such as Aschkenasy et al. (2011), that 
administration of exogenous HSP 70 with 266 μg/kg on septic mice 
model increased the number of BCL-2, which inhibited apoptosis [6]. 
Similarly, Choudhury et al. (2011) reported that the administration 
of exogenous of HSP70 inhibited apoptosis, by preventing the release 
of Cyt C complex, apoptotic protease-activating factor 1 (Apaf 1), 
procaspase 9, and caspase 3, respectively. Hence, caspase 3 is the 
immediate executor of apoptosis [12].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i11.27773
Research Article
184
Asian J Pharm Clin Res, Vol 11, Issue 11, 2018, 183-185
 Sukamto et al. 
Another author injected exogenous HSP70 with 266 μg/kg dose 10 min 
before and after the administration of intravenous 2 mg/kg dose 
lipopolysaccharides (LPS) reduced mortality of mice and modified 
some homeostasis and hemodynamic parameters [14].
In contrast to the beneficial effect of HSP, some studies have shown the 
deleterious adverse effect of HSP. For example, Lee et al. had shown an 
important issue in the association between H. pylori infection and a 
contradictive role of HSP as a good worker for defense against H. pylori 
infection and HSPs as a bad offender contributing to the progression of 
H. pylori-associated gastric carcinogenesis in addition to aggravation of 
gastric inflammation [15]. Therefore, there is a need to investigate the 
lesser dose of HSP 70 than 266 μg/kgBW that is still effective to prevent 
death.
This study aimed to determine the lowest effective dose of HSP 70 to 
prevent death in sepsis mice model with MODS, which was previously 
injected by intraperitoneal 0.25 mg/kgBW LPS.
METHODS
This was a randomized control trial conducted at Pusat Antar Universitas 
(PAU), Gadjah Mada University, Yogyakarta, Indonesia, from April 1 to 
21, 2017. The study subjects were Balb/c strain mice. The drug used to 
induce death was LPS from SIGMA L2880-10MG Lot #025M4040V from 
Escherichia coli 055:B5 purified by phenol extraction. The drug used to 
prevent death in this study was Rat HSP70 Lot#L16020515. A sample 
of 25 mice was randomized into five groups with each consisting of five 
mice:
• P0: Control group with NaCl;
• P1: Experimental group receiving LPS injection of 0.25 mg/kgBW/i.p;
• P2: Experimental group receiving LPS injection of 0.25 mg/kgBW/
intraperitoneal (ip) with HSP70 injection of 100 µg/kgBW/ip;
• P3: Experimental group receiving LPS injection of 0.25 mg/kgBW/
ip with HSP70 injection of 200 µg/kgBW/ip;
• P4: Experimental group receiving LPS injection of 0.25 mg/kgBW/
ip with HSP70 injection of 300 µg/kgBW/ip.
The percentage of live mice between groups was compared by Chi-
square test.
The Research Ethics Clearance for this study was granted by the Research 
Ethics Committee, Dr. Moewardi Hospital, Surakarta, Indonesia, 
number: 377/IV/HREC/2017. The handling of animal (mice) subject in 
this study followed “Guide for the Care and Use of Laboratory Animals” 
by National Research Council of the National Academies. Researchers 
conducting surgical procedures at PAU Laboratory, Gadjah Mada 
University, Yogyakarta, Indonesia, already had appropriate training 
to ensure that good surgical technique was practiced, that is, asepsis, 
gentle tissue handling, minimal dissection of tissue, appropriate use of 
instruments, effective hemostasis, and correct use of suture materials 
and patterns.
RESULTS
A total number of 25 male /c mice were examined in this experiment 
with ages ranging from 6 to 8 weeks and body weight 26–33 g. By day 
2, all of the mice were still alive in all study groups. However, by day 
3, some of the mice were dead with the distribution of dead mice as 
shown in Table 1.
Table 1 shows the results of Chi-square test comparing the proportion 
of alive mice between the four study groups after 3 days’ administration 
of HSP 70 with three different doses. The results show that the number 
and proportion of alive mice in i.p. 100 µg/kgBW HSP 70 group (3, 
60%) were higher than the non-HSP 70 group (2, 40%), but it was 
statistically non-significant (OR=2.25; p=0.527). Next, Table 1 shows 
that the number and proportion of alive mice in i.p. 200 µg/kgBW 
HSP 70 group (5, 100%) were higher than the non-HSP 70 group (2, 
40%), and it was statistically significant (OR=15.40; p=0.038). Mice 
with i.p. 200 µg/kgBW HSP 70 were 15.40 times more likely to survive 
than those without HSP 70 of such dose. Finally, Table 1 shows that 
the number and proportion of alive mice in i.p. 300 µg/kgBW HSP 70 
group (5, 100%) were higher than the non-HSP 70 group (2, 40%), 
and it was statistically significant (OR=15.40; p=0.038). Mice with 
i.p. 300 µg/kgBW HSP 70 were 15.40 times more likely to survive than 
those without HSP 70 of such dose.
Since the incremental HSP 70 dose increase from i.p. 200 µg/kgBW HSP 
70 to i.p. 300 µg/kgBW HSP 70 did not result in an increased survival 
of mice, then it was concluded that the optimal HSP 70 dose to prevent 
mice mortality was i.p. 200 µg/kgBW HSP 70.
DISCUSSION
In this study, the administration of LPS was intended to induce sepsis 
and eventually MODS in mice under the study. LPS is the main element 
of Gram-negative bacterial outer membrane [16]. As a study has 
shown, Gram-negative bacteria cause 30%–80% of sepsis [17]. Sepsis 
is a complex and serious problem that immediately leads to some 
states of metabolic change, including MODS, septic shock, and death, 
respectively [1,2]. The longer MODS is diagnosed, the higher mortality 
rates, which range from 25% to 80% [18].
In multiple organ dysfunction syndrome, the apoptosis process occurs 
through intrinsic pathway (i.e., mitochondria pathway) [1,19,20]. In 
an apoptosis mitochondria, Bcl-2 homologous antagonist killer (Bak) 
and BAX molecules constitute the BCL2 pro-apoptosis protein family 
[21-23]. Activation of homo-oligomerized Bak and BAX has its role 
in the pore formation of the outer mitochondria membrane. In this 
process, pro-apoptosis molecules are released, including Smac/Diablo 
and Cyt c. The Cyt c release leads to an activated caspase. The activated 
caspase is a sort of protease, which divides the key cellular protein that 
determines the apoptosis morphology [24].
HSP70 has been widely known to inhibit apoptosis both at the upstream 
and downstream of mitochondria. For example, a study has shown that 
266 μg/kgBW exogenous HSP70 can increase the number of BCL-2 
that inhibits apoptosis [7]. In this instance, exogenous HSP70 inhibits 
apoptosis by preventing the release of Cyt c, Apaf 1, procaspase 9, and 
caspase 3 complex. In turn, HSP70 binds Apaf-1, blocks apoptosome, 
and prevents Caspase 3 activation so that the downstream apoptosis is 
aborted [12,14].
In theory, HSP70 has its important role both at the upstream and 
downstream mitochondria along the stress-induced apoptosis pathway 
by preventing mouse death with an optimal dose of ip 200 µg/kgBW 
HSP70. In effect, homeostasis becomes balanced, and MODS treatment 
becomes more rapid and effective with the MODS-induced mortality 
substantially reduced.
CONCLUSION
This study gives evidence that the administration of both the ip 
200 μg/kgBW HSP70 and 300 μg/kgBW HSP70 were able to make 
Table 1: The results of Chi‑square test comparing the 
proportion of alive mice between the four study groups after 
3 days’ administration of HSP 70 with three different doses




n (%) n (%)
No HSP 70 2 (40) 3 (60) 5 (100) 1.00 1.00
HSP 70 100 µg/kgBW/ip 3 (60) 2 (40) 5 (100) 2.25 0.527
HSP 70 200 µg/kgBW/ip 5 (100) 0 (0) 5 (100) 15.40 0.038
HSP 70 300 µg/kgBW/ip 5 (100) 0 (0) 5 (100) 15.40 0.038
HSP: Heat Shock Protein, ip: Intraperitoneal
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mice to survive up to 3 days after intervention. However, the optimal 
dose to prevent mortality is ip 200 µg/kgBW HSP70. Further studies 
are suggested to investigate the effect of ip 200 µg/kgBW HSP70 on 
reducing Cyt C, BAX, and Caspase 3 expressions rather than using ip 
266 μg/kgBW HSP 70 dose, to better understand the intermediate 
pathways that lead to mortality.
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